Dr. Gilles Martin
Chief Executive Officer
Replay available
Eurofins Scientific Sa (OTC: ERFSF) Q3 2025 earnings conference call, held 2025-10-21. Replay captured from the company's public earnings webcast.

Chief Executive Officer
Analyst, Goldman Sachs
Analyst, Barclays
Analyst, Bank of America
Analyst, Citi
Analyst, Jefferies
Ladies and gentlemen, welcome and thank you for joining Eurofins' nine-month 2025 trading. I believe that this call is being recorded and will later be available for replay on the Eurofins Investor Relations website. Throughout today's presentation, all participants will be in a listen-only mode. The presentation will be followed by a question and answer session. If you would like to ask a question, you may press star followed by zero to register for questions. For operator assistance, please press the star key followed by zero. During this call, Eurofins management may make forward-looking statements including, but not limited to, statements with respect to outlook and the related assumptions. Management will also discuss alternative performance measures such as organic growth and EBITDA, which are defined in the footnotes of our press releases. Actual results may differ materially from objectives discussed. Risks and uncertainties that may affect Eurofins' future results include, but are not limited to, those described in the risk factors section of the most recent Eurofins annual and half-year reports. Please also read the disclaimer on page two of this presentation, subject to which this call and Q&A session are made. I would now like to turn the conference over to Dr. Gilles Martin, Eurofins CEO. Please go ahead. Hello, everybody, and thank you for joining our quarterly call. We have posted a small presentation. For those who are interested, I will refer to some of those slides. I will start on slide three. So I'm happy to report on a good quarter, which is in line with our plans. We've made good progress on all our initiatives. As you know, we are in the middle of our five years plan to build a world-class network of laboratories in our core market. We continue...